Ocular misses estimates for Q4 earnings, but beats on rev

Shares in Ocular Therapeutix (NSDQ:OCUL) fell today after the biopharmaceutical company missed earnings expectations, but beat sales estimates on Wall Street with its 4th quarter results.

The Bedford, Mass.-based company posted losses of -$-12.8 million, or -52¢ per share, on sales of $0.5 million for the 3 months ended Dec. 31, for bottom-line loss of -20.5% on sales growth of 17% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -52¢, behind consensus on The Street, where analysts were looking for sales of $0.48 million.

Get the full story at our sister site, Drug Delivery Business News.

The post Ocular misses estimates for Q4 earnings, but beats on rev appeared first on MassDevice.

from MassDevice http://ift.tt/2murfoN